Advertisement

ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER/HER2+ Breast Cancer

Published:February 13, 2019DOI:https://doi.org/10.1016/j.clbc.2019.02.001

      Abstract

      Background

      Human epidermal growth factor receptor 2–positive (HER2+) breast cancer is generally treated with HER2-targeted therapy combined with chemotherapy. Patients with HER2+ and estrogen receptor–positive (ER+) cancer are additionally treated with long-term hormone therapy. This study examined the metastatic pattern and prognosis of both ER+/HER2+ and ER/HER2+ breast cancer.

      Patients and Methods

      A total of 54,147 patients with HER2+ breast cancer from the National Cancer Data Base (NCDB, 2010-2013) and 31,946 patients with HER2+ breast cancer from the Surveillance, Epidemiology, and End Results Program (SEER, 2010-2014) were examined. Sites of metastasis and overall survival (OS) were examined in the NCDB, while OS and breast cancer–specific survival were examined in the SEER database.

      Results

      Compared to ER/HER2+ breast cancer, ER+/HER2+ breast cancer was more likely to metastasize to bone but less likely to brain, liver, and lung and less likely to result in multiple metastases. In univariate analysis based on the NCDB, patients with ER/HER2+ breast cancer had worse OS in all metastasis subsets, including patients who received HER2-targeted therapy. This poor survival for ER/HER2+ persisted in patients with metastasis to bone and lung, and multiple metastases. In multivariate analysis adjusting for age, tumor grade, surgery, chemotherapy, HER2-targeted therapy, and hormone therapy, ER/HER2+ patients with bone metastasis still had worse OS. In the SEER, ER/HER2+ patients had both worse OS and breast cancer–specific survival in univariate analysis.

      Conclusion

      This large study showed patients with ER+/HER2+ and ER/HER2+ breast cancers had different metastatic patterns. Patients with ER/HER2+ breast cancer may require more aggressive treatment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fitzmaurice C.
        • Dicker D.
        • et al.
        • Global Burden of Disease Cancer Collaboration
        The global burden of cancer, 2013.
        JAMA Oncol. 2015; 1: 505-527
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Dawood S.
        • Haaland B.
        • Albaracin C.
        • et al.
        Is the proportion of patients diagnosed with synchronous stage iv breast cancer who survive more than two years increasing over time?.
        Oncology. 2015; 89: 79-87
        • Ruiterkamp J.
        • Ernst M.F.
        • de Munck L.
        • et al.
        Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands.
        Breast Cancer Res Treat. 2011; 128: 495-503
        • Kennecke H.
        • Yerushalmi R.
        • Woods R.
        • et al.
        Metastatic behavior of breast cancer subtypes.
        J Clin Oncol. 2010; 28: 3271-3277
        • Falck A.K.
        • Bendahl P.O.
        • Chebil G.
        • Olsson H.
        • Ferno M.
        • Ryden L.
        Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up.
        Breast Cancer Res Treat. 2013; 140: 93-104
        • Li X.
        • Zhang Y.
        • Meisel J.
        • Jiang R.
        • Behera M.
        • Peng L.
        Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
        Breast Cancer Res Treat. 2018; 171: 303-313
        • Li X.
        • Yang J.
        • Krishnamurti U.
        • et al.
        Hormone receptor–positive breast cancer has a worse prognosis in male than in female patients.
        Clin Breast Cancer. 2017; 17: 356-366
        • Li X.
        • Yang J.
        • Peng L.
        • et al.
        Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
        Breast Cancer Res Treat. 2017; 161: 279-287
        • Sorlie T.
        Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
        Eur J Cancer. 2004; 40: 2667-2675
        • Chia S.K.
        • Speers C.H.
        • D’Yachkova Y.
        • et al.
        The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.
        Cancer. 2007; 110: 973-979
        • Beatson G.T.
        On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases.
        Trans Med Chir Soc Edinb. 1896; 15: 153-179
        • Jordan V.C.
        Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer.
        Br J Pharmacol. 2006; 147: S269-S276
        • Early Breast Cancer Trialists’ Collaborative Group
        Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
        Lancet. 2011; 378: 771-784
        • Slamon D.J.
        • Clark G.M.
        • Wong S.G.
        • Levin W.J.
        • Ullrich A.
        • McGuire W.L.
        Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
        Science. 1987; 35: 177-182
        • Slamon D.J.
        • Leyland-Jones B.
        • Shak S.
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Swain S.M.
        • Baselga J.
        • Kim S.B.
        • et al.
        Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
        N Engl J Med. 2015; 372: 724-734
        • Vona-Davis L.
        • Rose D.P.
        • Gadiyaram V.
        • et al.
        Breast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian population.
        J Cancer Epidemiol. 2014; 2014: 1-9
        • Vaz-Luis I.
        • Ottesen R.A.
        • Hughes M.E.
        • et al.
        Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
        J Clin Oncol. 2014; 32: 2142-2150
        • Kono M.
        • Fujii T.
        • Matsuda N.
        • et al.
        Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.
        J Cancer. 2018; 9: 3640-3646
        • Kast K.
        • Link T.
        • Friedrich K.
        • et al.
        Impact of breast cancer subtypes and patterns of metastasis on outcome.
        Breast Cancer Res Treat. 2015; 150: 621-629
        • Wu Q.
        • Li J.
        • Zhu S.
        • et al.
        Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
        Oncotarget. 2017; 8: 27990-27996
        • Smid M.
        • Wang Y.
        • Zhang Y.
        • et al.
        Subtypes of breast cancer show preferential site of relapse.
        Cancer Res. 2008; 68: 3108-3114
        • Garcia Fernandez A.
        • Gimenez N.
        • Fraile M.
        • et al.
        Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and HER2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
        Breast. 2012; 21: 366-373
        • Gong Y.
        • Liu Y.R.
        • Ji P.
        • Hu X.
        • Shao Z.M.
        Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study.
        Sci Rep. 2017; 7: 45411
        • Savci-Heijink C.D.
        • Halfwerk H.
        • Hooijer G.K.
        • Horlings H.M.
        • Wesseling J.
        • van de Vijver M.J.
        Retrospective analysis of metastatic behaviour of breast cancer subtypes.
        Breast Cancer Res Treat. 2015; 150: 547-557
        • Xiao W.
        • Zheng S.
        • Yang A.
        • et al.
        Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study.
        Cancer Manage Res. 2018; 10: 5329-5338
        • Molnar I.A.
        • Molnar B.A.
        • Vizkeleti L.
        • et al.
        Breast carcinoma subtypes show different patterns of metastatic behavior.
        Virchows Arch. 2017; 470: 275-283
        • Sorlie T.
        • Perou C.M.
        • Tibshirani R.
        • et al.
        Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
        Proc Natl Acad Sci U S A. 2001; 98: 10869-10874
        • Lobbezoo D.J.
        • van Kampen R.J.
        • Voogd A.C.
        • et al.
        Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
        Breast Cancer Res Treat. 2013; 141: 507-514
        • Sanpaolo P.
        • Barbieri V.
        • Genovesi D.
        Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
        Eur J Surg Oncol. 2011; 37: 876-882
        • Shou J.
        • Massarweh S.
        • Osborne C.K.
        • et al.
        Mechanisms of tamoxifen resistance: increased estrogen receptor–HER2/neu cross-talk in ER/HER2-positive breast cancer.
        J Natl Cancer Inst. 2004; 96: 926-935
        • Arpino G.
        • Green S.J.
        • Allred D.C.
        • et al.
        HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor–positive metastatic breast cancer: a Southwest Oncology Group study.
        Clin Cancer Res. 2004; 10: 5670-5676
        • Borg A.
        • Baldetorp B.
        • Fernö M.
        • et al.
        ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.
        Cancer Lett. 1994; 81: 137-144
        • Gianni L.
        • Pienkowski T.
        • Im Y.H.
        • et al.
        Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2012; 13: 25-32
        • Denkert C.
        • Huober J.
        • Loibl S.
        • et al.
        HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer.
        Breast Cancer Res. 2013; 15: R11
        • Freedman R.A.
        • Hughes M.E.
        • Ottesen R.A.
        • et al.
        Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network.
        Cancer. 2013; 119: 839-846